Skip To Main Content
al. Dysphagia on Muck Rack

al. Dysphagia

As seen in: Stockhouse, Stockwatch
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to al. Dysphagia’s profile

Articles by al. Dysphagia

RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

|
By Ye GH, al. Outcomes, al. Dysphagia
| Stockhouse
Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and resistance seen in 80 to 90 percent of HNSCC , /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study showing deep and durable responses with...
Open in Who Shared View Duplicates (420) Issue with article?
Show More